Canaccord Genuity Stake in Verici Dx Drops to 6.88% Following AIM Share Dilution

Canaccord Genuity's Voting Interest in Verici Dx Falls Below the 10% Threshold

The TR-1 notification confirms that Canaccord Genuity Group Inc, headquartered in Vancouver, Canada, has crossed a major shareholding threshold in Verici Dx plc. The group's total voting rights, held entirely through shares rather than financial instruments, now stand at 6.8843% of the company's total issued voting capital. This compares with the previously notified position of 10.3825%, representing a reduction of approximately 3.5 percentage points.

The notification is significant because it marks the crossing of both the 10% and 7% thresholds under the UK's Disclosure Guidance and Transparency Rules (DTR5). Under DTR5, any natural person or Legal entity that crosses a notifiable threshold — whether upwards or downwards — must disclose that change to the issuer and to the FCA. The filing was completed in Blackpool, England, on 24 June 2026, the day after the threshold was crossed.

Dilution From New AIM Share Admission Drives the Threshold Crossing

Crucially, the announcement makes clear that Canaccord Genuity did not sell any shares in Verici Dx. The filing states explicitly in Section 11: "The change in the percentage of shares held is due entirely to dilution, caused by the admission of new shares to trading on AIM on 23/06/2026." This is a material distinction for investors attempting to interpret the notification. A passive dilution arising from a capital raise is a fundamentally different signal from a decision by a major institutional shareholder to exit or reduce its position.

The number of voting rights held by Canaccord Genuity and its discretionary clients actually remains fixed at 157,465,837 shares. What has changed is the denominator — the total number of shares in issue — which has grown following the admission of new shares. The implication is that Verici Dx completed a share issuance or placing on 23 June 2026 that meaningfully expanded the company's Share Capital. The announcement does not disclose the size of the placing, the price per share, or the proceeds raised, so investors seeking those figures should refer to any separate fundraising announcement issued by Verici Dx.

The Chain of Controlled Entities Through Which the Stake Is Held

The TR-1 form sets out in detail the chain of corporate entities through which Canaccord Genuity Group Inc ultimately holds its economic and voting interest in Verici Dx. The chain runs from Canaccord Genuity Group Inc at the top, through Canaccord Genuity Limited (which holds 0.0148% directly), and then through Canaccord Genuity Wealth Group Holdings Limited, Canaccord Genuity Wealth Group Holdings (Jersey) Limited, Canaccord Genuity Wealth Group Limited, and finally Canaccord Genuity Asset Management Limited — each of the last four entities showing a combined stake of 6.8695%.

The disclosure suggests that the overwhelming majority of the interest is held through the wealth and asset management arm of the Canaccord group, with a very minor direct holding of 0.0148% sitting at the Canaccord Genuity Limited level. The voting rights are attributed to the underlying discretionary clients of those entities, as named in Section 4 of the form. This structure is commonplace for major Investment banks and wealth managers who hold shares on behalf of managed accounts rather than on the firm's own Balance Sheet.

Verici Dx and Its Position on AIM

Verici Dx plc is a transplant diagnostics company listed on the London Stock Exchange's AIM market. The company has been developing non-invasive diagnostic tools targeting kidney transplant outcomes, including tests designed to predict and detect rejection episodes. As a clinical-stage diagnostics Business, Verici Dx has been dependent on access to Capital Markets to fund its Research and Development activities, and capital raises on AIM have been a recurring feature of its corporate history.

The admission of new shares to AIM on 23 June 2026, which triggered this notification, would represent a further exercise of that capital-raising function. However, the announcement does not contain any information about the terms, purpose, or participants in the share issuance. Investors who require full details of any fundraising should consult the relevant primary RNS announcement from Verici Dx itself.

What the Remaining 6.8843% Stake Signals for Canaccord's Ongoing Interest

Whilst the headline percentage has fallen materially — from above 10% to below 7% — Canaccord Genuity remains one of Verici Dx's more substantial shareholders at 6.8843%. The absolute number of shares held by Canaccord's discretionary clients, at 157,465,837, is unchanged. This means that Canaccord's managed clients continue to hold a meaningful economic position in the company, and there is no indication in the filing that any decision has been made to reduce that holding.

Investors may be watching whether Canaccord Genuity will participate in any further capital raises at Verici Dx, or whether the dilution from the 23 June 2026 admission represents the beginning of a longer-term reduction in proportionate exposure. The announcement provides no guidance on this point, and it would be speculative to draw conclusions beyond what is stated in the filing.

Regulatory Framework Governing the TR-1 Disclosure Obligation

The TR-1 notification is a standard regulatory requirement under the FCA's Disclosure Guidance and Transparency Rules, specifically DTR5. These rules require any person or entity whose direct or indirect holding of voting rights in a UK-listed issuer crosses or reaches certain thresholds — set at 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, and each percentage point thereafter up to 100% — to notify both the issuer and the FCA as soon as possible, and no later than four trading days after the threshold is crossed.

In this case, the threshold was crossed on 23 June 2026, and the issuer was notified on 24 June 2026 — the following day — placing the notification well within the required timeframe. The form identifies the reason for the notification as "an event changing the breakdown of voting rights", which is the appropriate category when a dilutive share issuance, rather than a purchase or sale by the notifying party, causes a threshold to be crossed.

Canaccord Genuity Group Inc: Corporate Background and UK Presence

Canaccord Genuity Group Inc is a Canadian-headquartered global financial services firm with a substantial UK presence through its Wealth Management and capital markets divisions. The group is one of the more active participants in the AIM ecosystem, regularly acting as broker, nomad, or placing agent for smaller listed companies, as well as holding stakes on behalf of its discretionary wealth management clients. Its UK subsidiaries include Canaccord Genuity Limited and Canaccord Genuity Asset Management Limited, both of which feature in the chain of controlled entities disclosed in this notification.

The filing notes that Canaccord Genuity Group Inc is not controlled by any natural person or legal entity for the purposes of this disclosure, and that the holding is structured through a fully disclosed chain of subsidiaries. The completeness of the chain disclosure is a requirement under DTR5 and allows Market Participants and regulators to trace the ultimate beneficial ownership of the voting rights in question.

Implications for Verici Dx's Capital Structure Following the June 2026 Share Issuance

The fact that Canaccord Genuity's previously notified 10.3825% stake has been diluted to 6.8843% allows for a rough inference about the scale of the new share issuance. Working backwards from the disclosed absolute holding of 157,465,837 shares, the implied total voting rights in Verici Dx following the admission can be estimated. At 6.8843%, a holding of 157,465,837 shares implies a total share capital of approximately 2.287 billion shares. The company did not disclose this figure in the announcement, and investors should treat any such calculation as approximate and subject to confirmation from primary sources.

For context, if Canaccord's 157,465,837 shares previously represented 10.3825% of the total, the share capital before the admission would have implied approximately 1.517 billion shares. The difference between these two figures would represent the approximate number of new shares admitted on 23 June 2026. Again, the announcement does not disclose this figure, and investors should refer to Verici Dx's own disclosures for precise capital table information.

How Investors Should Interpret Major Shareholding Notifications of This Type

TR-1 notifications can sometimes be misread as signals of negative sentiment from a major shareholder. In this case, the explicit statement in the filing that the change is "due entirely to dilution" is an important clarification. Canaccord Genuity has not chosen to sell shares; its proportionate interest has simply been reduced by the mathematical effect of a larger share count. This is a passive event from Canaccord's perspective and does not, on its own, indicate any change in the firm's view of Verici Dx's prospects or value.

The immediate share price impact was not clear from available public information. Investors monitoring Verici Dx's shareholder register and capital structure developments may wish to track whether any further TR-1 notifications are filed in the coming weeks, either from Canaccord Genuity or from new investors who may have participated in the 23 June 2026 share admission. Any such filings would provide additional colour on the evolving ownership dynamics of the company.